Updated:
Verana Health
Verana Health builds exclusive clinical databases from society partnerships, using AI to power real-world evidence and clinical trials for pharma.
Verana Health
Verana Health was founded with the mission to aggregate and analyze real-world clinical data from electronic health records. The firm’s founding principal, Mark Blumenkranz, MD, co-founded the company alongside Lagunita Biosciences, and the current CEO is Sujay Jadhav, who joined after leading Oracle’s Health Sciences Business Unit. The company partners exclusively with the American Academy of Ophthalmology (IRIS Registry) and the American Urological Association (AQUA Registry), among others, to manage data from over 20,000 clinicians. Its solutions span real-world evidence generation, clinical trial enablement, and quality reporting, serving the top four of five pharmaceutical companies (per firm website, 2025). Verana Health operates across ophthalmology, urology, and neurology, with an expanding oncology division led by Chief Medical Officer C.K. Wang, who joined through the merger with COTA. Verana Health’s network covers roughly 90 million de-identified patients with up to 10 years of longitudinal data. Its team includes leaders from goBalto (acquired by Oracle) and Flatiron Health. In January 2024, the firm introduced an expanded ovarian cancer dataset and has since launched disease-specific modules for bladder and prostate cancers (per firm website, 2025). The company is backed by investors including Kleiner Perkins, GV, Novo Holdings, and Deerfield Management. The firm’s structural differentiator lies in its exclusive, long-term data partnerships with medical specialty societies, giving it access to clinician-directed, near-real-time data that competitors cannot license. This closed-loop data engine, combined with AI enrichment, allows Verana to offer research-ready datasets and services that integrate across the drug lifecycle — a model distinct from either standalone CROs or generic health data brokers.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Francisco
Corporate office
33 New Montgomery St #1550, San Francisco, CA 94105, United States
Additional offices
New York, NY · Knoxville, TN
Principals
Sujay Jadhav
Chief Executive Officer
David W. Parke II
Executive Chairman
Sector focus
Frequently asked questions
Who leads investment decisions at Verana Health?
Investment and strategic decisions are led by CEO Sujay Jadhav, who joined in 2021. The board includes representatives from major investors such as Kleiner Perkins, GV, Novo Holdings, and Deerfield Management. Executive Chairman David W. Parke II, former CEO of the American Academy of Ophthalmology, provides oversight. The firm does not disclose an internal investment committee or CIO role.
How does Verana Health source its data?
Verana Health obtains data through exclusive partnerships with medical specialty societies, including the American Academy of Ophthalmology and the American Urological Association. It manages the IRIS Registry (ophthalmology) and AQUA Registry (urology), collecting de-identified electronic health record data from over 20,000 clinicians. This exclusive access means competitors cannot license the same datasets.
Is Verana Health structured as a family office or a venture-backed company?
Verana Health is a venture-backed digital health company, not a family office. Its investors include institutional venture capital firms (Kleiner Perkins, GV, Novo Holdings) and corporate venture arms (Johnson & Johnson Innovation, Merck). The firm does not have a disclosed single-family-office backer.
What therapeutic areas does Verana Health cover?
The firm’s core therapeutic areas are ophthalmology and urology, via its exclusive society partnerships. It has since expanded into neurology and oncology, the latter led by Chief Medical Officer C.K. Wang following a merger with COTA. Oncology datasets now include bladder, ovarian, and prostate cancer.
Does Verana Health provide services to pharmaceutical companies?
Yes. Verana Health serves life sciences companies with real-world evidence studies, clinical trial site selection, patient recruitment, and commercialization analytics. The firm states that the top four of five largest pharmaceutical companies are customers (per firm website, 2025). It also offers MIPS quality reporting for clinicians and registry management for medical societies.
Who are Verana Health’s main competitors?
Verana Health competes with other real-world data and evidence firms such as Flatiron Health (oncology-focused, now part of Roche), IQVIA, and COTA (which it merged with). Its exclusive society partnerships create a moat in ophthalmology and urology that competitors cannot easily replicate. The firm differentiates through clinician-directed data curation and AI-driven data integrity loops.
How does Verana Health use artificial intelligence?
Verana Health applies AI and machine learning to structure and enrich clinical data from electronic health records. Its platform, VeraQ, uses AI for natural language processing of unstructured clinical notes and to power a data integrity feedback loop. The firm has also introduced AI agents for tasks such as MIPS submission compliance and site selection for trials.
What is Verana Health's geographic footprint?
Verana Health is headquartered in San Francisco, CA, with additional offices in New York, NY and Knoxville, TN. Its data network covers clinicians across the United States, with no disclosed international operations. Patients in the network are de-identified and sourced from U.S. healthcare providers.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: